logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HR+ metastatic breast cancer: meta-analysis finds survival benefit with CDK4/6 inhibitors plus ET

A meta-analysis of 9 phase 2 or 3 RCTs with 5043 patients.